Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Oil Up Over U.S. Crude Stockpiles Decrease, OPEC+ Optimism

Published 04/13/2021, 10:12 PM
Updated 04/13/2021, 10:19 PM
© Reuters.

By Gina Lee

Investing.com – Oil was up Wednesday morning in Asia, as investors cheered a decline in U.S. crude oil supplies. Rising numbers of COVID-19 cases and the latest hurdle in the COVID-19 vaccine program triggered fuel demand worries, however.

Brent oil futures gained 0.66% to $64.09 by 10:13 PM ET (2:13 AM GMT) and WTI futures rose 0.68% to $60.59, surpassing the $60 mark.

U.S. crude oil supply data from the American Petroleum Institute showed a draw of 3.608 million barrels for the week ending Apr. 9. Forecasts prepared by Investing.com had predicted a draw of 2.15 million barrels, while a 2.618-barrel-draw was recorded during the previous week.

Supply data from the U.S. Energy Information Administration is due later in the day, which is widely expected to confirm a third consecutive weekly draw.

The Organization of Petroleum Exporting Countries and allies (OPEC+)’s monthly report, released on Tuesday, boosted consumption forecast for 2021 and predicted the market recovery will continue in the coming months.

The report added that increasing consumption should help to keep stockpiles low, even as the cartel prepares to ease production curbs from May onwards.

“It was a welcome prognosis by the market, which had been fretting about the impact the ongoing COVID-19 was having on demand,” ANZ Research analysts said in a note.

COVID-19 could still have the last word, however, as some countries struggle to contain new waves of the virus. India, the third-largest oil importer globally, continues to see high numbers of cases in its second wave,

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The global COVID-19 vaccine rollout has also hit a bump in the road, as the U.S. Centers for Disease Control and Prevention and FDA on Tuesday hit pause on the use of the Johnson & Johnson (NYSE:JNJ) offering. The pair halted the rollout after six women who received it developed a rare and severe form of blood clotting, and the pause is expected to last for a few days.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.